Analysis of several pretreatment factors may help predict the prognosis of patients treated with ytrrium-90 (Y-90) radioembolization for liver metastases from colorectal cancer. Prediction of outcomes after radioembolization has been difficult, with previous studies identifying various factors.… Read More
Cryoablation is an effective way to control pain from cancer without major side effects, according to the results of a systemic review. Analgesics can control most cancer pain, but patients with bone metastases often struggle with quality-of-life issues from uncontrolled pain. However,… Read More
Transradial access
Transradial access and transfemoral access led to similar levels of patient radiation exposure during transarterial yttrium-90 (Y-90) radioembolization (TARE), researchers found. Selective internal radiation therapy for hepatocellular carcinoma and other hepatic tumors has the potential to expose… Read More
Chemoembolization with polyethylene glycol (PEG) drug-eluting embolic agents is a safe and effective treatment for hepatocellular carcinoma (HCC), researchers reported. The investigators conducted a single-center, retrospective study that took place during a 20-month period. There were 302… Read More
Child with IV
Transarterial chemoembolization (TACE) seems to be a safe and effective treatment option to manage hepatic tumor burden and for downstaging and bridging to liver transplantation in children with unresectable hepatocellular carcinoma (HCC). Children with HCC who are not resectable and cannot… Read More
When treated with yttrium-90 (Y90) transarterial radioembolization (TARE), patients with hepatic soft tissue sarcoma (STS) of the liver had high rates of demonstrated disease control, as well as a median overall survival of 30 months. Although Y-90 TARE is accepted as an effective treatment for… Read More
Researchers report that the use of a stiffening cannula (Cook, Ind. USA) can safely and efficiently recanalize occluded transjugular intrahepatic portosystemic shunts (TIPS) in situations in which conventional lesion crossing is not possible. Although TIPS has a technical success rate of 95% when… Read More
liver cancer
The results of the palliative cohort of the SORAMIC study indicate that there is no confirmed clinical advantage to combining selective internal radiation therapy (SIRT) with standard sorafenib versus treatment with sorafenib alone. However, a subgroup analysis suggests a benefit for the combined… Read More
The FDA has approved the combination of nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb Co.) to treat intermediate- or poor-risk advanced renal cell carcinoma that was previously untreated. The approval is based on data from the randomized, open-label CheckMate 214 trial, which… Read More
renal cell carcinoma
Computed tomography (CT)-guided percutaneous microwave ablation has a treatment response that is similar to that of radiofrequency ablation or cryoablation for the treatment of stage T1N0M0 renal cell carcinoma. Additionally, patients who underwent microwave ablation experienced shorter treatment… Read More